Clinical Trial

Single and Twice-daily Dosing of Ramipril on Renal Function in Chronic Kidney Disease Patients With Reduced Ejection Fraction Heart Failure

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated December 10, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study compares the effects of once-daily versus twice-daily ramipril dosing on renal function in chronic kidney disease (CKD) patients with heart failure with reduced ejection fraction (HFrEF). Outcomes include changes in plasma renin activity, malondialdehyde, interleukin-6, albuminuria, and cystatin C after 30 days of therapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-20.
Trial Details
NCT Number NCT07259512
Lead Sponsor Evi Liliek Wulandari
Conditions Chronic Kidney Disease, Heart Failure With Reduced Ejection Fraction (HFrEF)
Enrollment 80 participants
Start Date 2025-06-30
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-01-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-10